Jacqueline serves as the Lead Analyst of the China Healthcare team, covering pharma, biotech, devices, Traditional Chinese Medicine (TCM), and health care services, across both H & A shares. Prior to joining Huatai Securities, she worked in the Global Research Department of HSBC and CICC (Shanghai).

Jacqueline has a Bachelor of Science in Biological Sciences, and a Ph.D. in Nanoscience Technology from Hong Kong University of Science and Technology.

In the 2020 poll, her team was ranked #2 Best Analyst Team under Healthcare category (mainland). In 2019, Jacqueline placed second in the Institutional Investor All-China poll in her sector (mainland) and runner-up (international). She placed 1st and 2nd in 2017 and 2018, for the institutional investors “All China” category.